Indoco Remedies · NSE: INDOCO · BSE: 532612
Q2 FY23 results · Jul–Sep 2022
Indoco Remedies reported revenue from operations of ₹433.04 crore (up 11.9% from Q2 FY22) and net profit of ₹49.73 crore (up 19.3% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 433.04 | 386.87 | +11.9% | 408.22 | +6.1% |
| Other income | 0.35 | 1.01 | −65.3% | 1.13 | −69.0% |
| Total income | 433.39 | 387.88 | +11.7% | 409.35 | +5.9% |
| Profit before tax | 67.30 | 64.95 | +3.6% | 48.35 | +39.2% |
| Net profit for the period | 49.73 | 41.69 | +19.3% | 38.57 | +28.9% |
| EPS, basic (₹) | 5.40 | 4.52 | +19.5% | 4.19 | +28.9% |
| Net margin (%) | 11.5 | 10.8 | 9.4 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 432.69 | 386.59 | +11.9% | 407.90 | +6.1% |
| Other income | 0.34 | 1.01 | −66.3% | 1.13 | −69.9% |
| Total income | 433.03 | 387.60 | +11.7% | 409.03 | +5.9% |
| Profit before tax | 67.20 | 64.81 | +3.7% | 48.20 | +39.4% |
| Net profit for the period | 49.64 | 41.57 | +19.4% | 38.47 | +29.0% |
| EPS, basic (₹) | 5.39 | 4.51 | +19.5% | 4.17 | +29.3% |
| Net margin (%) | 11.5 | 10.8 | 9.4 |
Consolidated
- Filed with BSE
- 10 Nov 2022, 18:03 IST
- Board meeting
- 10 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Nov 2022, 18:03 IST
- Board meeting
- 10 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE